Point72 Asset Management L.P. Purchases Shares of 167,892 Monopar Therapeutics Inc. (NASDAQ:MNPR)

Point72 Asset Management L.P. bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 167,892 shares of the company's stock, valued at approximately $3,694,000. Point72 Asset Management L.P. owned 2.75% of Monopar Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in MNPR. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $23,435,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics in the 4th quarter worth about $13,182,000. RA Capital Management L.P. acquired a new stake in Monopar Therapeutics in the 4th quarter valued at about $11,247,000. ADAR1 Capital Management LLC purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $2,861,000. Finally, Geode Capital Management LLC raised its position in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after acquiring an additional 24,530 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Price Performance

MNPR traded up $0.01 during trading hours on Monday, hitting $35.45. 14,864 shares of the stock were exchanged, compared to its average volume of 360,848. The stock has a market cap of $216.78 million, a price-to-earnings ratio of -17.99 and a beta of 1.11. The stock has a 50-day simple moving average of $37.93 and a 200-day simple moving average of $32.58. Monopar Therapeutics Inc. has a 12 month low of $1.72 and a 12 month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.27. Sell-side analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Insider Transactions at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the transaction, the insider now owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 20.50% of the company's stock.

Analysts Set New Price Targets

MNPR has been the topic of several recent research reports. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday. Finally, HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $55.33.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.